Auteurs
Louis J - Doudka N - Félix MS - Spiga Ghata A - Espanet C - Guilhaumou R - Milh M - Villard L
Journal
Epilepsia open
Abstract
Carbamazepine is the first line treatment for patients affected by KCNQ2 developmental and epileptic encephalopathy. It is efficient to reduce or stop seizures in this context. However, its effect on the neurodevelopmental outcomes is debated. The aim of this study was to evaluate the efficacy of long-term oral administration of carbamazepine in a mouse model of Kcnq2 dysfunction.